Baby Dead In Restroom At Store Near Fort Hood

Tumblr: Yahoo's reported $1B bid to be cool Yahoo has agreed to buy popular social blogging service Tumblr for $1.1 billion in a high-stakes move to regain the company's relevancy in an Internet environment now dominated by Google, Facebook and Twitter. Yahoo has "wanted something that has Facebook and Twitter like features for many years," said Ross Rubin, founder and principal analyst at Reticle Research of New York. According to the research firm Quantcast, 29 percent of Tumblr's members are ages 18 to 24 and another 19 percent are under 18. Yahoo's previous foray into social networking was a product called Yahoo 360, which the company launched in 2005, but abandoned in 2008 after it failed to gain traction. [] Solis said if Mayer and Yahoo "can infuse business expertise into the community without disrupting it, Yahoo and Tumblr will increase revenues that, according to industry forecasts, will help it recoup acquisition costs." [] Rubin also noted that Yahoo has struggled in the past to prosper with high-profile acquisitions, such as buying Flickr in 2005 when "it was by far the leading online photo community, and Instagram came out of nowhere to surpass it." Bloomberg News reported that Yahoo called Monday's press conference to unveil enhancements to its photo-sharing service Flickr, which has more than 80 million monthly users.

An officer’s decision to enter a home in Uniondale, N.Y., and open fire, killing a gunman and a student being held hostage, may have eliminated the opportunity to negotiate with the gunman, some experts said.    

The forecast calls for the dense fog to lift around 8 a.m. Monday, then partly sunny skies with a high near 84 degrees.

A report says former Navy Secretary Richard J. Danzig, who serves as a bio-warfare adviser to the president and Pentagon, urged the government to stockpile an anti-anthrax drug while serving as a director for the company that supplies it.

Report: Bio-warfare adviser warned US of threat of new anthrax while on board of drug maker